Contineum Therapeutics Q3 EPS $(3.55), Cash Position $117.9M
$CTNM
Biotechnology: Pharmaceutical Preparations
Health Care
Contineum Therapeutics Q3 EPS $(3.55), Cash Position $117.9M
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/22/2024 | $32.00 | Outperform | Robert W. Baird |
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced participation in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-6, 2024, NY, NY: Carmine Stengone, Contineum's President and CEO, will present on Wednesday, September 4, 2024, at 7:00 am ET. H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, NY, NY:
- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl - - Strong cash position of $219 million at the end of Q2 will support multiple clinical readouts - Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "Our tea
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced encouraging preclinical data on PIPE-307, a potentially first-in-class M1 receptor antagonist in development for patients with relapse-remitting multiple sclerosis (RRMS), were published online in the peer-reviewed journal, Proceedings of the National Academy of Science (PNAS). The published data provide early evidence that PIPE-307 is a potentially first-
Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
3 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
10-Q - Contineum Therapeutics, Inc. (0001855175) (Filer)
8-K/A - Contineum Therapeutics, Inc. (0001855175) (Filer)
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors and as Chair of the Audit Committee. Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum's board. "I am extremely pleased to welcome Troy to the Contineum board. Troy's recent public markets experience, coupled with his proven t